Belgium-based iTeos Therapeutics SA has raised $75 million in an oversubscribed Series B financing round to advance two of its immunotherapy candidates into the clinic and open a new office in Cambridge, Massachusetts, US.
The funding was led by MPM Capital with participation from the additional new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All of the company’s existing investors also participated in the round.